Amgen Inc.
AMGNAmgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Drugs in Pipeline
196
Phase 3 Programs
117
Upcoming Catalysts
18
Next Catalyst
Feb 28, 2026
10dMarket Overview
Stock performance and key metrics
19 upcoming, 1 past
Conference Presentation
Amgen will present at Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, with Jean-Charles Soria, senior vice president of oncology within global development, as the presenter.
sotorasib Phase 2 Results Expected
Primary completion for sotorasib trial (NCT03600883) in KRAS p.G12C Mutant Advanced Solid Tumors
Source17 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Lumakras
Sotorasib
KRAS G12C NSCLC
Ustekinumab
Psoriasis
Rosuvastatin
Hyperlipidemia
Trifluridine and Tipiracil
Colorectal Cancer (CRC)
Apremilast (CC-10004)
Behcet Syndrome
Rocatinlimab
Asthma
Carboplatin
Non-small Cell Lung Cancer Metastatic
Vincrisitne
Leukemia, Acute Lymphoblastic
Lanadelumab
COVID-19
Topical Therapy
Plaque Psoriasis
Lenalidomide
Relapsed Multiple Myeloma
MP-376 (Levofloxacin Solution for Inhalation)
Cystic Fibrosis
FOLFOX regimen
Metastatic Colorectal Cancer
RP103
Cystinosis
Blinatumomab
Acute Lymphoblastic Leukemia
Adalimumab
Plaque Psoriasis
AMG 073
Secondary Hyperparathyroidism
Aranesp®
Kidney Disease
rHuEPO
Cancer
Apremilast 20mg
Psoriatic Arthritis
Evolocumab AMD
Primary Hypercholesterolemia
De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease
Apremilast 30mg
Psoriatic Arthritis
Background Statin Therapy
Dyslipidemia
ABP 938
Neovascular (Wet) Age-related Macular Degeneration (AMD)
darbepoetin alfa
Anemia
Cystagon®
Cystinosis
60 mg denosumab
Low Bone Mass
Chemotherapy
Gastric Cancer
Zoledronic Acid
Bone Metastases
Best Supportive Care
Multiple Myeloma
Denosumab
Osteoporosis
mFOLFOX6
Gastric Cancer
Aflibercept
Chorioretinal Vascular Disease
Oxaliplatin Based Chemotherapy
Colorectal Cancer
Etanercept Liquid
Rheumatoid Arthritis
Romosozumab 90 mg/mL
Postmenopausal Osteoporosis
Topical treatments or phototherapy
Plaque Psoriasis
Standard Chemotherapy
Cancer
Recombinant Human Keratinocyte Growth Factor
Stomatitis
etanercept pre-filled syringe subcutaneous injection
Rheumatoid Arthritis
Anakinra (Kineret®)
Rheumatoid Arthritis
Atorvastatin
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
AMG 162 / Denosumab
Breast Cancer
Teprotumumab
Thyroid Eye Disease
1=Etanercept
Psoriasis
FOLFIRI
Metastatic Colorectal Cancer
Non-steroidal aromatase inhibitor therapy
Breast Cancer
Ibuprofen/famotidine
Ulcer
Statin therapy
Coronary Artery Disease (CAD)
interferon γ-1b
Friedreich's Ataxia
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
pegfilgrastim
Breast Cancer
Ibandronate
Postmenopausal Osteoporosis
ABP 710
Arthritis, Rheumatoid
Sotorasib
Non-small Cell Lung Cancer
Inebilizumab
IgG4 Related Disease
Darbepoetin alfa - 2.25 mcg/kg
Anemia
Xaluritamig
Metastatic Castration-resistant Prostate Cancer
ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Pembrolizumab
Melanoma
Ezetimibe
Hyperlipidemia
ABP 501
Arthritis, Rheumatoid
Dazodalibep
Sjögren's Syndrome (SS)
Topical agents
Psoriasis
Aranesp® (darbepoetin alfa)
Kidney Disease
AMG 162
Postmenopausal Osteoporosis
Cinacalcet HCl
Kidney Disease
Olpasiran
Cardiovascular Disease
HPN-100
Cirrhosis
AMG 386
Ovarian Cancer
Cetuximab
Metastatic Colorectal Cancer
Dexamethasone
Relapsed and Refractory Multiple Myeloma
Low-intensity chemotherapy regimen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Palifermin
Head and Neck Cancer
Romiplostim
Chemotherapy-induced Thrombocytopenia
AMG 531
Thrombocytopenia
Etoposide
Small-cell Lung Cancer
Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Bemarituzumab
Gastric Cancer
Etanercept
Rheumatoid Arthritis
alendronate
Osteoporosis
Erenumab
Migraine
ABP 206
Melanoma
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Apremilast 30 mg
Psoriatic Arthritis
Aeroquin
Cystic Fibrosis
Commercial Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
ABP 959
Paroxysmal Nocturnal Hemoglobinuria
Apremilast
Behçet's Disease
Etelcalcetide
Secondary Hyperparathyroidism
Daratumumab
Relapsed Multiple Myeloma
Panitumumab
Metastatic Colorectal Cancer
Tarlatamab
Small Cell Lung Cancer
Methotrexate
Psoriatic Arthritis
Cinacalcet
End Stage Renal Disease
Evolocumab Pre-filled Syringe
Primary Hypercholesterolemia
Cystagon® (Cysteamine Bitartrate)
Cystinosis
Romozosumab
Postmenopausal Osteoporosis
Carfilzomib
Multiple Myeloma
Apremilast tablet 20 mg
Ankylosing Spondyloarthritis
Evolocumab
Hyperlipidemia
Buphenyl (NaPBA)
Urea Cycle Disorders
Paclitaxel
Locally Recurrent and Metastatic Breast Cancer
darbepoetin alfa SF
Kidney Disease
Darbepoetin alfa and Epoetin alfa
Anemia
FOLFIRI Regimen
Metastatic Colorectal Cancer
MR prednisone
Rheumatoid Arthritis
HZT-501
Osteoarthritis
50 mg Etanercept
Rheumatoid Arthritis
Epoetin alfa DT
Chronic Kidney Disease
Avacopan
Vasculitis
Lurbinectedin
Small Cell Lung Cancer (SCLC)
Romosozumab
Postmenopausal Women With Osteoporosis
ABP 798
Arthritis, Rheumatoid
Bortezomib
Multiple Myeloma
Abiraterone
Metastatic Castration-resistant Prostate Cancer
ABP 980
Breast Cancer
AMG 102
Cancer
Adecatumumab
Liver Metastases
AMG 531 (Romiplostim)
MDS
IV Bisphosphonates
Breast Cancer
Darbepoetin alfa SC
Anemia
pegfilgrastim 12 mg
Lymphoma
Sunitinib
Advanced Renal Cell Carcinoma
Panitumumab (ABX-EGF)
Advanced Renal Cell Carcinoma
AMG 853
Asthma
epratuzumab
Non-Hodgkin's Lymphoma
cinacalcet (AMG 073)
Secondary Hyperparathyroidism
VIB7734
Lupus Erythematosus, Systemic
Modified FOLFOX6
Advanced Solid Tumors
AMG 827
Asthma
IV Bisphosphonate q 4 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Pegsunercept (PEG sTNF-RI)
Rheumatoid Arthritis
MP-376
Cystic Fibrosis (CF)
Teriparatide
Low Bone Mineral Density
CCX140-B
Diabetic Nephropathy
AMG 102 at 10 mg/kg
Advanced Renal Cell Carcinoma
AMG 655
Metastatic Colorectal Cancer
BUPHENYL®
Urea Cycle Disorders
CCX-354-C
Rheumatoid Arthritis
100 mg AMG 162
Osteoporosis
filgrastim
Sarcoma
ABX-EGF
Non-small Cell Lung Cancer
VIB4920
Sjögren's Syndrome
Belatacept
Allografts
Conatumumab
Colon Cancer
cyclophosphamide
Breast Cancer
AMG 714
Psoriasis
AMG 719
Rheumatoid Arthritis
AMG 732
Thyroid Eye Disease
Abrilumab
Ulcerative Colitis
Brodalumab
Rheumatoid Arthritis
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Anemia
Tezepelumab Dose 1
Chronic Spontaneous Urticaria
Recombinant Human Erythropoietin
Breast Cancer
Irinotecan
Metastatic Colorectal Cancer
CCX168
Vasculitis
ABX-EGF (panitumumab)
Metastatic Colorectal Cancer
IDE397
MTAP-null Non-Small-Cell Lung Cancer
recombinant human erythropoietin (rHuEPO)
Gynecological Malignancies
AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
HZN-1116
Sjogren's Syndrome
Gemcitabine
Lung Cancer
Cisplatin
Squamous Cell Carcinoma of Head and Neck
pioglitazone
Type 2 Diabetes Mellitus
Talimogene laherparepvec
Melanoma
AMG 193
MTAP-deleted NSCLC
Systemic AMG 108
Osteoarthritis
Blinatumomab (MT103)
Acute Lymphoblastic Leukemia
anakinra
Rheumatoid Arthritis
Liatermin
Parkinson's Disease
Daxdilimab
Alopecia Areata
AMG 151
Diabetes Mellitus
Intra-articular metHuIL-1ra (anakinra)
Osteoarthritis
Docetaxel
Advanced MTAP-null Solid Tumors
IV iron dextran
Anemia
Pemetrexed
Non Small Cell Lung Cancer
Neulasta
Breast Cancer
Erenumab PFS
Migraine
AMG 102 at 20 mg/kg
Advanced Malignant Glioma
CCX 354-C
Rheumatoid Arthritis
AMG 706
Gastrointestinal Cancer
AMG 386 10mg/kg
Gastrointestinal Cancer
Naproxen
Bone Pain in Stage I - III Breast Cancer
CC-10004
Psoriasis
Oprozomib
Multiple Myeloma
Previous denosumab
Low Bone Mass
AMG 108
Rheumatoid Arthritis
Sorafenib
Advanced Hepatocellular Carcinoma
Lodotra
Asthma
CCX282-B
Crohn's Disease
AMG 223
End Stage Renal Disease
Motesanib diphosphate
Lung Cancer
Rozibafusp Alfa
Systemic Lupus Erythematosus (SLE)
AMG 509
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumakras Sotorasib | Approved | KRAS G12C NSCLC | Fast TrackBreakthrough | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Rosuvastatin | Phase 3 | Hyperlipidemia | - | - |
Trifluridine and Tipiracil | Phase 3 | Colorectal Cancer (CRC) | - | - |
Apremilast (CC-10004) | Phase 3 | Behcet Syndrome | - | - |
Rocatinlimab | Phase 3 | Asthma | - | - |
Carboplatin | Phase 3 | Non-small Cell Lung Cancer Metastatic | - | - |
Vincrisitne | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Lanadelumab | Phase 3 | COVID-19 | - | - |
Topical Therapy | Phase 3 | Plaque Psoriasis | - | - |
Lenalidomide | Phase 3 | Relapsed Multiple Myeloma | - | - |
MP-376 (Levofloxacin Solution for Inhalation) | Phase 3 | Cystic Fibrosis | - | - |
FOLFOX regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
RP103 | Phase 3 | Cystinosis | - | - |
Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Adalimumab | Phase 3 | Plaque Psoriasis | - | - |
AMG 073 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Aranesp® | Phase 3 | Kidney Disease | - | - |
rHuEPO | Phase 3 | Cancer | - | - |
Apremilast 20mg | Phase 3 | Psoriatic Arthritis | - | - |
Evolocumab AMD | Phase 3 | Primary Hypercholesterolemia | - | - |
De Novo Administration of Darbepoetin Alfa | Phase 3 | Chronic Kidney Disease | - | - |
Apremilast 30mg | Phase 3 | Psoriatic Arthritis | - | - |
Background Statin Therapy | Phase 3 | Dyslipidemia | - | - |
ABP 938 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
Cystagon® | Phase 3 | Cystinosis | - | - |
60 mg denosumab | Phase 3 | Low Bone Mass | - | - |
Chemotherapy | Phase 3 | Gastric Cancer | - | - |
Zoledronic Acid | Phase 3 | Bone Metastases | - | - |
Best Supportive Care | Phase 3 | Multiple Myeloma | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
mFOLFOX6 | Phase 3 | Gastric Cancer | - | - |
Aflibercept | Phase 3 | Chorioretinal Vascular Disease | - | - |
Oxaliplatin Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
Etanercept Liquid | Phase 3 | Rheumatoid Arthritis | - | - |
Romosozumab 90 mg/mL | Phase 3 | Postmenopausal Osteoporosis | - | - |
Topical treatments or phototherapy | Phase 3 | Plaque Psoriasis | - | - |
Standard Chemotherapy | Phase 3 | Cancer | - | - |
Recombinant Human Keratinocyte Growth Factor | Phase 3 | Stomatitis | - | - |
etanercept pre-filled syringe subcutaneous injection | Phase 3 | Rheumatoid Arthritis | - | - |
Anakinra (Kineret®) | Phase 3 | Rheumatoid Arthritis | - | - |
Atorvastatin | Phase 3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | - | - |
AMG 162 / Denosumab | Phase 3 | Breast Cancer | - | - |
Teprotumumab | Phase 3 | Thyroid Eye Disease | - | - |
1=Etanercept | Phase 3 | Psoriasis | - | - |
FOLFIRI | Phase 3 | Metastatic Colorectal Cancer | - | - |
Non-steroidal aromatase inhibitor therapy | Phase 3 | Breast Cancer | - | - |
Ibuprofen/famotidine | Phase 3 | Ulcer | - | - |
Statin therapy | Phase 3 | Coronary Artery Disease (CAD) | - | - |
interferon γ-1b | Phase 3 | Friedreich's Ataxia | - | - |
Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
pegfilgrastim | Phase 3 | Breast Cancer | - | - |
Ibandronate | Phase 3 | Postmenopausal Osteoporosis | - | - |
ABP 710 | Phase 3 | Arthritis, Rheumatoid | - | - |
Sotorasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Inebilizumab | Phase 3 | IgG4 Related Disease | - | - |
Darbepoetin alfa - 2.25 mcg/kg | Phase 3 | Anemia | - | - |
Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | - | - |
Pembrolizumab | Phase 3 | Melanoma | - | - |
Ezetimibe | Phase 3 | Hyperlipidemia | - | - |
ABP 501 | Phase 3 | Arthritis, Rheumatoid | - | - |
Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | - | - |
Topical agents | Phase 3 | Psoriasis | - | - |
Aranesp® (darbepoetin alfa) | Phase 3 | Kidney Disease | - | - |
AMG 162 | Phase 3 | Postmenopausal Osteoporosis | - | - |
Cinacalcet HCl | Phase 3 | Kidney Disease | - | - |
Olpasiran | Phase 3 | Cardiovascular Disease | - | - |
HPN-100 | Phase 3 | Cirrhosis | - | - |
AMG 386 | Phase 3 | Ovarian Cancer | - | - |
Cetuximab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Dexamethasone | Phase 3 | Relapsed and Refractory Multiple Myeloma | - | - |
Low-intensity chemotherapy regimen | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | - | - |
Palifermin | Phase 3 | Head and Neck Cancer | - | - |
Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
AMG 531 | Phase 3 | Thrombocytopenia | - | - |
Etoposide | Phase 3 | Small-cell Lung Cancer | - | - |
Cysteamine Bitartrate Delayed-release Capsules | Phase 3 | Cystinosis | - | - |
Bemarituzumab | Phase 3 | Gastric Cancer | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
alendronate | Phase 3 | Osteoporosis | - | - |
Erenumab | Phase 3 | Migraine | - | - |
ABP 206 | Phase 3 | Melanoma | - | - |
Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | - | - |
Apremilast 30 mg | Phase 3 | Psoriatic Arthritis | - | - |
Aeroquin | Phase 3 | Cystic Fibrosis | - | - |
Commercial Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
ABP 959 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Apremilast | Phase 3 | Behçet's Disease | - | - |
Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | - | - |
Daratumumab | Phase 3 | Relapsed Multiple Myeloma | - | - |
Panitumumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Tarlatamab | Phase 3 | Small Cell Lung Cancer | OrphanFast TrackBreakthrough | |
Methotrexate | Phase 3 | Psoriatic Arthritis | - | - |
Cinacalcet | Phase 3 | End Stage Renal Disease | - | - |
Evolocumab Pre-filled Syringe | Phase 3 | Primary Hypercholesterolemia | - | - |
Cystagon® (Cysteamine Bitartrate) | Phase 3 | Cystinosis | - | - |
Romozosumab | Phase 3 | Postmenopausal Osteoporosis | - | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - | - |
Apremilast tablet 20 mg | Phase 3 | Ankylosing Spondyloarthritis | - | - |
Evolocumab | Phase 3 | Hyperlipidemia | - | - |
Buphenyl (NaPBA) | Phase 3 | Urea Cycle Disorders | - | - |
Paclitaxel | Phase 3 | Locally Recurrent and Metastatic Breast Cancer | - | - |
darbepoetin alfa SF | Phase 3 | Kidney Disease | - | - |
Darbepoetin alfa and Epoetin alfa | Phase 3 | Anemia | - | - |
FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
MR prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
HZT-501 | Phase 3 | Osteoarthritis | - | - |
50 mg Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Epoetin alfa DT | Phase 3 | Chronic Kidney Disease | - | - |
Avacopan | Phase 3 | Vasculitis | - | - |
Lurbinectedin | Phase 3 | Small Cell Lung Cancer (SCLC) | - | - |
Romosozumab | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
ABP 798 | Phase 3 | Arthritis, Rheumatoid | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Abiraterone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
ABP 980 | Phase 3 | Breast Cancer | - | - |
AMG 102 | Phase 2 | Cancer | - | - |
Adecatumumab | Phase 2 | Liver Metastases | - | - |
AMG 531 (Romiplostim) | Phase 2 | MDS | - | - |
IV Bisphosphonates | Phase 2 | Breast Cancer | - | - |
Darbepoetin alfa SC | Phase 2 | Anemia | - | - |
pegfilgrastim 12 mg | Phase 2 | Lymphoma | - | - |
Sunitinib | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
Panitumumab (ABX-EGF) | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 853 | Phase 2 | Asthma | - | - |
epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
cinacalcet (AMG 073) | Phase 2 | Secondary Hyperparathyroidism | - | - |
VIB7734 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Modified FOLFOX6 | Phase 2 | Advanced Solid Tumors | - | - |
AMG 827 | Phase 2 | Asthma | - | - |
IV Bisphosphonate q 4 weeks | Phase 2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | - | - |
Pegsunercept (PEG sTNF-RI) | Phase 2 | Rheumatoid Arthritis | - | - |
MP-376 | Phase 2 | Cystic Fibrosis (CF) | - | - |
Teriparatide | Phase 2 | Low Bone Mineral Density | - | - |
CCX140-B | Phase 2 | Diabetic Nephropathy | - | - |
AMG 102 at 10 mg/kg | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 655 | Phase 2 | Metastatic Colorectal Cancer | - | - |
BUPHENYL® | Phase 2 | Urea Cycle Disorders | - | - |
CCX-354-C | Phase 2 | Rheumatoid Arthritis | - | - |
100 mg AMG 162 | Phase 2 | Osteoporosis | - | - |
filgrastim | Phase 2 | Sarcoma | - | - |
ABX-EGF | Phase 2 | Non-small Cell Lung Cancer | - | - |
VIB4920 | Phase 2 | Sjögren's Syndrome | - | - |
Belatacept | Phase 2 | Allografts | - | - |
Conatumumab | Phase 2 | Colon Cancer | - | - |
cyclophosphamide | Phase 2 | Breast Cancer | - | - |
AMG 714 | Phase 2 | Psoriasis | - | - |
AMG 719 | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 732 | Phase 2 | Thyroid Eye Disease | - | - |
Abrilumab | Phase 2 | Ulcerative Colitis | - | - |
Brodalumab | Phase 2 | Rheumatoid Arthritis | - | - |
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Phase 2 | Anemia | - | - |
Tezepelumab Dose 1 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
Recombinant Human Erythropoietin | Phase 2 | Breast Cancer | - | - |
Irinotecan | Phase 2 | Metastatic Colorectal Cancer | - | - |
CCX168 | Phase 2 | Vasculitis | - | - |
ABX-EGF (panitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
IDE397 | Phase 2 | MTAP-null Non-Small-Cell Lung Cancer | - | - |
recombinant human erythropoietin (rHuEPO) | Phase 2 | Gynecological Malignancies | - | - |
AMG 951 (rhApo2L/TRAIL) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
HZN-1116 | Phase 2 | Sjogren's Syndrome | - | - |
Gemcitabine | Phase 2 | Lung Cancer | - | - |
Cisplatin | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
pioglitazone | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Talimogene laherparepvec | Phase 2 | Melanoma | - | - |
AMG 193 | Phase 2 | MTAP-deleted NSCLC | - | - |
Systemic AMG 108 | Phase 2 | Osteoarthritis | - | - |
Blinatumomab (MT103) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
anakinra | Phase 2 | Rheumatoid Arthritis | - | - |
Liatermin | Phase 2 | Parkinson's Disease | - | - |
Daxdilimab | Phase 2 | Alopecia Areata | - | - |
AMG 151 | Phase 2 | Diabetes Mellitus | - | - |
Intra-articular metHuIL-1ra (anakinra) | Phase 2 | Osteoarthritis | - | - |
Docetaxel | Phase 2 | Advanced MTAP-null Solid Tumors | - | - |
IV iron dextran | Phase 2 | Anemia | - | - |
Pemetrexed | Phase 2 | Non Small Cell Lung Cancer | - | - |
Neulasta | Phase 2 | Breast Cancer | - | - |
Erenumab PFS | Phase 2 | Migraine | - | - |
AMG 102 at 20 mg/kg | Phase 2 | Advanced Malignant Glioma | - | - |
CCX 354-C | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 706 | Phase 2 | Gastrointestinal Cancer | - | - |
AMG 386 10mg/kg | Phase 2 | Gastrointestinal Cancer | - | - |
Naproxen | Phase 2 | Bone Pain in Stage I - III Breast Cancer | - | - |
CC-10004 | Phase 2 | Psoriasis | - | - |
Oprozomib | Phase 2 | Multiple Myeloma | - | - |
Previous denosumab | Phase 2 | Low Bone Mass | - | - |
AMG 108 | Phase 2 | Rheumatoid Arthritis | - | - |
Sorafenib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Lodotra | Phase 2 | Asthma | - | - |
CCX282-B | Phase 2 | Crohn's Disease | - | - |
AMG 223 | Phase 2 | End Stage Renal Disease | - | - |
Motesanib diphosphate | Phase 2 | Lung Cancer | - | - |
Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
AMG 509 | Phase 1 | Prostate Cancer | Fast Track | - |
KRAS G12C NSCLC
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Prostate Cancer
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)